News

Cenix conducts contract research and develops technology for RNA interference (RNAi), miRNA modulation and high content phenotyping to accelerate target discovery, target validation, and the non-clinical development of

Biosimilars are drugs whose effects are similar to those of biopharmaceuticals and are sold by a different manufacturer once the original drugs’ patent expires, pharmalive.com reported. The joint

Under the agreement, both the companies will boost the clinical development besides increasing productivity and cost effectiveness. UCB will receive the benefits of PAREXEL’s clinical processes through all

Menerba, an oral, estrogen receptor beta (ER-b) selective drug candidate is developed to treat vasomotor symptoms (hot flashes) associated with menopause, which is manufactured from botanical sources. The

The first patent covers a class of compounds that combine elements of diketopiperazines and methylphenidate derivatives, while the second patent is directed to novel derivatives of methylphenidate (Ritalin).

The company recently filed its first provisional patent application for use of anti-adhesion molecule therapies to treat FIV infections, and has identified three candidate antibodies that are likely

Both the companies will discover, develop and commercialize synthetic siRNA directed towards an undisclosed target for the treatment of glaucoma. Once Sylentis exercises this option, Alnylam will be

The two companies entered into a drug discovery and development collaboration on May 2008 with an aim to discover new treatments for neuropsychiatric disorders. PsychoGenics evaluated a library

The cream is helpful in providing relief to burning, itching and pain caused in different types of skin conditions, including atopic dermatitis (eczema), allergic contact dermatitis and radiation